Clinical Trials Logo

Osteoarthritis clinical trials

View clinical trials related to Osteoarthritis.

Filter by:

NCT ID: NCT04872855 Active, not recruiting - Clinical trials for Total Knee Arthroplasty

Observational Study to Evaluate Clinical Performance and Safety in Total Knee Arthroplasty

Start date: July 17, 2020
Phase:
Study type: Observational

The aim of this study is to assess the long-term performance and safety of HLS KneeTec cementless and hybrid fixation knee prosthesis when used in standard medical practice.

NCT ID: NCT04864392 Active, not recruiting - Osteoarthritis Clinical Trials

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

ONWARDS
Start date: May 31, 2021
Phase: Phase 2
Study type: Interventional

The study will determine the optimal dosing regimen of LNA043 in patients with knee osteoarthritis (OA).

NCT ID: NCT04837053 Active, not recruiting - Knee Osteoarthritis Clinical Trials

Implementation of Indication Criteria for Total Knee Replacement in Osteoarthritis (Value-based TKR)

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The aim of this trial is to investigate the effect of a medical decision aid (EKIT-Tool) on decision quality for knee arthroplasty.

NCT ID: NCT04817969 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Persona Ti-Nidium Post-Market Clinical Follow-up

TKA
Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The main objectives of this study are to evaluate overall clinical performance and safety of the Persona Ti-Nidium implant in total knee arthroplasty.

NCT ID: NCT04815902 Active, not recruiting - Clinical trials for Osteoarthritis, Knee

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

Start date: May 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, randomized, double-blind, active control clinical trial to evaluate the safety and efficacy of a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently and in combination, to improve beneficial effect demonstrated by the active control which is to be injection of autologous bone marrow aspirate concentrate (BMAC) into an osteoarthritic knee.

NCT ID: NCT04814719 Active, not recruiting - Clinical trials for Osteoarthritis, Knee

An Observational Follow-up Study to Evaluate Duration of Treatment Effect of Pentosan Polysulfate Sodium in Participants With Knee Osteoarthritis Pain

Start date: June 24, 2023
Phase:
Study type: Observational

The purpose of this study is to measure the duration of treatment effect with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with placebo in adult participants with knee osteoarthritis (OA) pain. The study duration will be up to 34 weeks. Participants who completed pDay 162 of Study PARA_OA_002 (i.e. did not discontinue/withdraw prematurely from the parent study) will be invited to participate.

NCT ID: NCT04814368 Active, not recruiting - Knee Osteoarthritis Clinical Trials

A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)

Start date: August 27, 2021
Phase: Phase 2
Study type: Interventional

The study will establish safety and efficacy of canakinumab and LNA043 in patients with knee osteoarthritis (OA).

NCT ID: NCT04809376 Active, not recruiting - Clinical trials for Osteoarthritis, Knee

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Start date: October 19, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee osteoarthritis pain. Study details include: - The study duration will be up to 31 weeks per participant - The treatment duration will be 6 weeks. - The visit frequency will be twice weekly during treatment. - The visit frequency will be every 4 weeks during the follow-up period.

NCT ID: NCT04789837 Active, not recruiting - Osteoarthritis Clinical Trials

The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis

Start date: March 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Cilostazol is able to suppress the degradation of type II collagen in human chondrocytes induced by IL-1b. Cilostazol add-on for celecoxib therapy has synergistic anti-arthritic potential by inhibiting proinflammatory cytokine production in synovial fibroblasts through the IL-10/SOCS3 pathways, consequently leading to the inhibition of synovial cell proliferation and overcoming the perpetuation of synovial inflammation.

NCT ID: NCT04784065 Active, not recruiting - Hand Osteoarthritis Clinical Trials

A Pilot Randomized Controlled Trial for Hand Osteoarthritis

Start date: February 11, 2021
Phase: N/A
Study type: Interventional

This is a study involving people receiving care at the Michael E. DeBakey VA Medical Center, Houston Texas. We are studying people who have hand osteoarthritis (the most common form of arthritis that involves the hand) and testing treatments for the condition with the hope that we can help to improve hand pain as well as limit the damage that occurs related to the arthritis. People who choose to participate, are randomly assigned to one of two treatments, both expected to be helpful.